Virtual healthcare platforms are redefining patient access to care, with Hims & Hers Health, Inc. HIMS and GoodRx Holdings, ...

GoodRx Holdings (GDRX) shares have slipped about 27% over the past month, drawing investor attention to recent performance trends. The company’s ongoing path sparks questions about how current ...

The company launched GoodRx for Weight Loss, a telemedicine subscription connecting consumers with licensed healthcare providers for weight management treatment. Additionally, GoodRx partnered with ...

GoodRx (NASDAQ:GDRX – Free Report) had its price target cut by Truist Financial from $6.50 to $5.50 in a research note published on Thursday,Benzinga reports. They currently have a hold rating on the ...

GoodRx GDRX recently rolled out a new e-commerce experience aimed at improving how consumers obtain their prescriptions through its platform. This upgraded system offers a more streamlined and ...

What Happened? A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies. These subsidies, which ...

GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of Ozempic (semaglutide) and Wegovy (semaglutide) pens are available to eligible ...

GoodRx (GDRX) is joining in on the GLP-1 action with an announcement on Monday that it will begin selling both of Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss, at ...

As the U.S. stock market continues its upward trajectory, with major indexes marking their biggest weekly rise since June, investors are increasingly exploring diverse opportunities to capitalize on ...

JP Morgan analyst Lisa C. Gill revised her 2025 outlook on GoodRx Holdings (NASDAQ:GDRX) following the company’s first-quarter earnings. Gill reaffirmed an Overweight rating on the stock and ...

Commonwealth Equity Services LLC reduced its stake in GoodRx Holdings, Inc. (NASDAQ:GDRX – Free Report) by 30.3% during the 4th quarter, Holdings Channel reports. The institutional investor owned ...

I'm reiterating my Buy rating on GoodRx, as its valuation is compelling and the business is showing signs of stabilization under new leadership. GoodRx's recurring revenue base, expanding pharma ...